Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic News - Page 3

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

October 10, 2022

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that

Read More
Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use Psychedeic-Chronicle-Logo-White
Psychedelic News

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

October 7, 2022

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy. Numinus strives to be at the cutting edge of psychedelic-assisted therapies

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial Psychedeic-Chronicle-Logo-White
October 7, 2022

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic DMT drug

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio Psychedeic-Chronicle-Logo-White
September 30, 2022

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio

Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Ketamine Wellness Centers KWC Launches New Directory of Ketamine Therapists Psychedeic-Chronicle-Logo-White
Psychedelic News

Ketamine Wellness Centers (KWC) Launches New Directory of Ketamine Therapists

The nation’s largest ketamine therapy provider now offers complimentary patient resources supporting holistic mental health treatment. On Thursday, the largest ketamine therapy

July 1, 2022
Tryp Therapeutics Announces Psilyocbin-Assisted Patent Application for Binge Eating Disorder Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Tryp Therapeutics Announces Psilyocbin-Assisted Patent Application for Binge Eating Disorder Treatment

Clinical-stage biotechnology Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) has strengthened their intellectual property portfolio with a new provisional patent designed to treat

June 30, 2022
Previous 1 2 3

Recent Posts

  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
  • Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Recent Comments

No comments to show.

Popular

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS